Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report
Open Access
- 8 March 2022
- journal article
- research article
- Published by Wiley in Clinical Case Reports
- Vol. 10 (3) , e05368
Abstract
Linear IgA/IgG bullous dermatosis (LAGBD) is a rare, autoimmune blistering skin disease. We report a case of LAGBD in a 70‐year‐old woman. All common treatments were discontinued due to side effects or lack of treatment response. The patient was successfully treated with omalizumab which cleared her lesions after three months.Keywords
All Related Versions
This publication has 11 references indexed in Scilit:
- High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive studyRheumatology International, 2020
- Increasing evidence for omalizumab in the treatment of bullous pemphigoidJAAD Case Reports, 2020
- Linear IgA bullous dermatosis successfully treated with omalizumab: A case reportJAAD Case Reports, 2019
- Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the LiteratureAmerican Journal of Clinical Dermatology, 2018
- Immunoglobulin E-Mediated AutoimmunityFrontiers in Immunology, 2018
- Bullous Pemphigoid: A Review of its Diagnosis, Associations and TreatmentAmerican Journal of Clinical Dermatology, 2017
- Three Cases of Linear IgA/IgG Bullous Dermatosis Showing IgA and IgG Reactivity With Multiple Antigens, Particularly Laminin-332JAMA Dermatology, 2013
- Linear immunoglobulin A bullous dermatosisClinics in Dermatology, 2012
- Localized Linear IgA/IgG Bullous DermatosisActa Dermato-Venereologica, 2010
- Antigenic Specificity of Antibodies from Patients with Linear Basement Membrane Deposition of IgADermatology, 1994